TopBP1-IN-3

TopBP1-IN-3 (compound 4B5) (5 μM; 20 h) selectively induces apoptosis in MDA-MB-468 triple-negative breast cancer cells and MDAH-2774 ovarian cancer cells, while exhibiting no apoptosis-inducing effect on untransformed AML12 mouse hepatocytes^[1].
TopBP1-IN-3 (preincubated at 4°C for 2 h, followed by overnight incubation with the phosphopeptide at 4°C) is a potent inhibitor that blocks the binding of TopBP1-BRCT7/8 to its physiological phosphorylated S1159 peptide ligand, with an IC₅₀ of 8 nM^[1].
TopBP1-IN-3 (pre-incubated for 2 h at 4°C, followed by overnight incubation with GST-mutp53R273H (DBD) at 4°C) effectively disrupts the oncogenic protein-protein interaction between TopBP1-BRCT7/8 and mutp53R273H (DBD), with an IC₅₀ of 0.3 μM^[1].
TopBP1-IN-3 (0.02-2.5 μM; initial treatment for 24 h, followed by 5 days of culture in compound-free medium) significantly inhibits the long-term clonogenic proliferation capacity of MDA-MB-468 triple-negative breast cancer cells, with its clonogenic survival IC₅₀ falling in the range of 1 to 2.5 μM, which is consistent with that of 4B4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.